CPRX vs. GMAB

Last updated Jun 4, 2026

CPRX (Catalyst Pharmaceuticals, Inc.) and GMAB (Genmab A/S) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 10 years, CPRX returned 48.24%/yr vs 2.42%/yr for GMAB. At a 0.15 correlation, their price movements are largely independent.

Performance

CPRX vs. GMAB - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Catalyst Pharmaceuticals, Inc. (CPRX) and Genmab A/S (GMAB). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, CPRX achieves a 34.02% return, which is significantly higher than GMAB's -22.47% return. Over the past 10 years, CPRX has outperformed GMAB with an annualized return of 48.24%, while GMAB has yielded a comparatively lower 2.42% annualized return.

CPRX

• 1D: 0.03%
• 1M: 8.09%
• YTD: 34.02%
• 6M: 35.41%
• 1Y: 25.57%
• 3Y*: 39.39%
• 5Y*: 41.68%
• 10Y*: 48.24%

GMAB

• 1D: 0.13%
• 1M: -11.69%
• YTD: -22.47%
• 6M: -24.62%
• 1Y: 11.85%
• 3Y*: -15.49%
• 5Y*: -10.22%
• 10Y*: 2.42%

*Multi-year figures are annualized to reflect compound growth (CAGR)

CPRX vs. GMAB - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
CPRX Catalyst Pharmaceuticals, Inc.	34.02%	11.84%	24.15%	-9.62%	174.74%	102.69%	-10.93%	95.31%	-50.90%	272.38%
GMAB Genmab A/S	-22.47%	47.58%	-34.45%	-24.87%	7.13%	-2.71%	82.09%	35.54%	-0.61%	-0.04%

Correlation

The correlation between CPRX and GMAB is 0.25, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.25
Correlation (3Y) Calculated over the trailing 3-year period	0.23
Correlation (5Y) Calculated over the trailing 5-year period	0.29
Correlation (10Y) Calculated over the trailing 10-year period	0.21
Correlation (All Time) Calculated using the full available price history since Jun 2, 2009	0.15

The correlation between CPRX and GMAB shifts across timeframes, from 0.15 (all time) to 0.29 (5 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap CPRX : $3.97B GMAB : $15.25B
EPS CPRX : $1.74 GMAB : $4.10
PE Ratio CPRX : 17.98 GMAB : 5.83
PEG Ratio CPRX : 0.32 GMAB : 0.39
PS Ratio CPRX : 6.67 GMAB : 1.72
PB Ratio CPRX : 3.92 GMAB : 2.68
Total Revenue (TTM) CPRX : $596.96M GMAB : $8.84B
Gross Profit (TTM) CPRX : $378.23M GMAB : $8.27B
EBITDA (TTM) CPRX : $313.50M GMAB : $3.81B

Return for Risk

CPRX vs. GMAB — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CPRX

CPRX Risk / Return Rank: 60
CPRX Sharpe Ratio Rank: 65
CPRX Sortino Ratio Rank: 59
CPRX Omega Ratio Rank: 59
CPRX Calmar Ratio Rank: 60
CPRX Martin Ratio Rank: 57

GMAB

GMAB Risk / Return Rank: 49
GMAB Sharpe Ratio Rank: 53
GMAB Sortino Ratio Rank: 47
GMAB Omega Ratio Rank: 45
GMAB Calmar Ratio Rank: 49
GMAB Martin Ratio Rank: 50

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CPRX vs. GMAB - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Catalyst Pharmaceuticals, Inc. (CPRX) and Genmab A/S (GMAB). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	CPRX	GMAB	Difference
Sharpe ratio Return per unit of total volatility	0.76	0.35	+0.42
Sortino ratio Return per unit of downside risk	1.25	0.71	+0.54
Omega ratio Gain probability vs. loss probability	1.16	1.09	+0.08
Calmar ratio Return relative to maximum drawdown	0.94	0.37	+0.58
Martin ratio Return relative to average drawdown	1.71	0.85	+0.87
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

CPRX vs. GMAB - Sharpe Ratio Comparison

The current CPRX Sharpe Ratio is 0.76, which is higher than the GMAB Sharpe Ratio of 0.35. The chart below compares the historical Sharpe Ratios of CPRX and GMAB, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	CPRX	GMAB	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.76	0.35	+0.42
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.88	-0.31	+1.18
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.80	0.07	+0.73
Sharpe Ratio (All Time) Calculated using the full available price history	0.09	0.26	-0.17

Drawdowns

CPRX vs. GMAB - Drawdown Comparison

The maximum CPRX drawdown since its inception was -94.25%, which is greater than GMAB's maximum drawdown of -84.20%. Use the drawdown chart below to compare losses from any high point for CPRX and GMAB.

Drawdown Indicators

	CPRX	GMAB	Difference
Max Drawdown Largest peak-to-trough decline	-94.25%	-84.20%	-10.05%
Max Drawdown (1Y) Largest decline over 1 year	-27.29%	-32.51%	+5.22%
Max Drawdown (3Y) Largest decline over 3 years	-27.29%	-57.44%	+30.15%
Max Drawdown (5Y) Largest decline over 5 years	-45.37%	-63.10%	+17.73%
Max Drawdown (10Y) Largest decline over 10 years	-64.87%	-63.10%	-1.77%
Current Drawdown Current decline from peak	-0.16%	-50.99%	+50.83%
Average Drawdown Average peak-to-trough decline	-52.05%	-31.07%	-20.98%
Ulcer Index Depth and duration of drawdowns from previous peaks	14.95%	14.03%	+0.92%

Volatility

CPRX vs. GMAB - Volatility Comparison

The current volatility for Catalyst Pharmaceuticals, Inc. (CPRX) is 6.81%, while Genmab A/S (GMAB) has a volatility of 11.99%. This indicates that CPRX experiences smaller price fluctuations and is considered to be less risky than GMAB based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	CPRX	GMAB	Difference
Volatility (1M) Calculated over the trailing 1-month period	6.81%	11.99%	-5.18%
Volatility (6M) Calculated over the trailing 6-month period	23.58%	25.15%	-1.57%
Volatility (1Y) Calculated over the trailing 1-year period	33.60%	34.23%	-0.63%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	47.86%	33.42%	+14.44%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	60.61%	35.23%	+25.38%

Dividends

CPRX vs. GMAB - Dividend Comparison

Neither CPRX nor GMAB has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

CPRX vs. GMAB - Profitability Comparison

The chart below illustrates the profitability comparison between Catalyst Pharmaceuticals, Inc. and Genmab A/S over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

CPRX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Catalyst Pharmaceuticals, Inc. reported a gross profit of 0.00 and revenue of 149.39M. Therefore, the gross margin over that period was 0.0%.

GMAB - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Genmab A/S reported a gross profit of 834.08M and revenue of 899.32M. Therefore, the gross margin over that period was 92.8%.

CPRX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Catalyst Pharmaceuticals, Inc. reported an operating income of 73.23M and revenue of 149.39M, resulting in an operating margin of 49.0%.

GMAB - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Genmab A/S reported an operating income of 225.83M and revenue of 899.32M, resulting in an operating margin of 25.1%.

CPRX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Catalyst Pharmaceuticals, Inc. reported a net income of 63.73M and revenue of 149.39M, resulting in a net margin of 42.7%.

GMAB - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Genmab A/S reported a net income of 53.20M and revenue of 899.32M, resulting in a net margin of 5.9%.

Frequently Asked Questions

Can I hold both CPRX and GMAB in my portfolio?

CPRX and GMAB have a correlation of 0.25, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, CPRX or GMAB?

GMAB has higher volatility (11.99%) compared to CPRX (6.81%). In terms of maximum drawdown, CPRX dropped -94.25% vs GMAB's -84.20%.

Which has better risk-adjusted returns?

CPRX currently has the higher Sharpe Ratio (0.76 vs 0.35), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.